Uveal melanoma: Current evidence on prognosis, treatment and potential developments

Asia-Pacific Journal of Ophthalmology, Journal Year: 2024, Volume and Issue: 13(2), P. 100060 - 100060

Published: March 1, 2024

Uveal Melanoma (UM) is a rare disease, yet it the most common primary intraocular malignancy in adult patients. Despite continuous advancements and research, risk of metastasis remains high. It possible to stratify patients according their metastases using variety known factors. Even though there no gold standard for prognostication with uveal melanoma, becoming increasingly clear that combining histo-pathological, patient-related molecular prognostic markers allows more accurate prediction metastatic than by one parameter. Primary UM eye are treated very effectively eye-sparing radiation-based techniques or enucleation. However, not prevent treat current therapeutic options. Nonetheless, efforts find new targets continue progress being made, especially field targeted therapy, as exemplified anti-gp100 bispecific molecule Tebentafusp. This review delves into history its incidence, presentation diagnosis, factors treatment options, both tumour metastases. We show different populations may have risks developing UM, each country should evaluate own

Language: Английский

---

Treatment of Conjunctival Melanoma Cell Lines With a Light-Activated Virus-Like Drug Conjugate Induces Immunogenic Cell Death

Investigative Ophthalmology & Visual Science, Journal Year: 2024, Volume and Issue: 65(13), P. 3 - 3

Published: Nov. 4, 2024

Purpose: Conjunctival melanoma (CJM) is a rare malignant ocular surface tumor, which often leads to local recurrences and metastases. In murine models of subcutaneous tumors, treatment with novel virus-like drug conjugate (VDC; Bel-sar) showed dual mechanism action direct tumor cell killing as well stimulation an antitumoral immune response. Bel-sar currently being evaluated for the primary uveal indeterminate nevi in phase III clinical trial. We determined whether also has antitumor efficiency potential immunostimulatory capacity CJM cells. Methods: Three human tumor-derived lines were used. Bel-sar's subcellular intracellular locations tracers. Following light activation Bel-sar, cytotoxicity exposure damage-associated molecular patterns (DAMPs) assessed. Treated cells co-cultured THP-1 derived macrophages assess tumor-cell phagocytosis. Results: was bound internalized by subsequently found membrane, lysosome, Golgi apparatus, mitochondria. induced near complete death half-maximal inhibitory concentration (IC50) values between 30 pM 60 pM. Finally, light-activated enhanced DAMPs, including calreticulin, heat shock protein 90, stimulated phagocytosis macrophages. Conclusions: Treatment VDC (Bel-sar) pro-immunogenic all three lines. The vitro accompanied suggesting action. This may provide targeted induce response might decrease metastasis.

Language: Английский

---

Targeting ocular malignancies using a novel light-activated virus-like drug conjugate

Advances in Ophthalmology Practice and Research, Journal Year: 2024, Volume and Issue: 5(1), P. 49 - 57

Published: Dec. 3, 2024

Targeted therapy is a promising approach to improve the treatment of tumors, including ocular malignancies. Current therapies, such as radiotherapy and surgery, often lead serious damage vision or loss eye. New approaches have examined nanoparticles for use targeted delivery vehicles drugs. A newly-developed virus-like drug conjugate nanoparticle with defined target: novel particle-photosensitizer Belzupacap sarotalocan (Bel-sar, previous name AU-011). In this review, we summarize application light-activated particle in pre-clinical clinical studies discuss its potential treat malignancies, uveal melanoma conjunctival melanoma. We furthermore combination immunotherapy on pigmented non-pigmented tumors well effect macrophage polarization, which important achieve effective results immunotherapy. (Bel-sar) carrier that enhances tumor-specific minimizes off-target effects. Its photodynamic effectively treats while inducing immunogenic cell death through DAMP exposure, triggering local systemic immune responses. Combining Bel-sar PDT improves efficacy preclinical models, warranting further investigation.

Language: Английский

---

Personalized ocular oncology care: how far have we come?

Canadian Journal of Ophthalmology, Journal Year: 2024, Volume and Issue: 59(5), P. e423 - e424

Published: May 26, 2024

Language: Английский

---